NVCR News and Press, NovoCure Limited From 11/21/19

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured...

In this week's episode of Industry Focus: Healthcare , host Shannon Jones talks with the Fool's med-tech guru, contributor Brian Feroldi, about three exciting companies listeners will want to add to their watch lists. Learn more about the businesses behind Cutera  (NASDAQ: CUTR) , Nov...

The biotech industry in Europe remains fragmented due to limited early stage capital and more risk-averse investor sentiment. While a small group of companies have successfully developed new products and financed adequate research and development, many other small ones struggle to get by with co...

China spent $137 billion on healthcare in 2018 and could spend up to $170 billion annually by 2023. Two exciting biotech companies ,  BeiGene (NASDAQ: BGNE)  and Zai Lab (NASDAQ: ZLAB) , allow investors an opportunity to get in on the action while it's still early. And why ...

NovoCure Limited (NVCR) Q3 2019 Earnings Conference Call October 31, 2019 8:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chief...

Image source: The Motley Fool. NovoCure Limited   (NASDAQ: NVCR) Q3 2019 Earnings Call Oct 31, 2019 , 8:00 a.m. ET Operator Continue reading

The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q3 earnings Read more ...

Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial mar...

NovoCure (NASDAQ: NVCR ) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is -$0.04 (+69.2% Y/Y) and the consensus Revenue Estimate is $87.12M (+34.5% Y/Y). Over the last 1 year, nvcr has beaten EPS estimates 0% of...